COEP: coeptistx.com Company Value to Net Income

Coeptis Therapeutics Inc. - graphic logo of issuer COEP

Coeptis Therapeutics (COEP) aims to expand its presence in the hematologic oncology cell therapy segment through the development of its NK platform. The company has assembled leading oncologists who create life-saving drugs in state-of-the-art laboratories. This price chart available on the page demonstrates a P/E ratio of -8.80. The business is currently focusing on the patent protection of its innovations, allowing it to avoid direct price wars with competitors.

COEP - Coeptis Therapeutics Price to Earnings Ratio over the range 04/28/2023 - 05/09/2026

Analytical breakdowns for Coeptis Therapeutics

Summary company analysis:Coeptis Therapeutics, Inc. COEP
Original product of Coeptis Therapeutics, Inc.

The diversified NK-cell therapy pipeline of Coeptis Therapeutics (COEP) minimizes regulatory threats, establishing a foundation for future capitalization. The ratio of market value to net income, reflected in the company's relative P/E valuation, measures the investment payback period and the market's willingness to pay a premium for growth potential, allowing for the identification of whether the asset is overbought or undervalued prior to the publication of official reports.